Beschreibung:
Aggressive lymphomas are clinically and biologically heterogenous entities, reflecting a diverse cell of-origins with multiple means of malignant transformation. With chemoimmunotherapy, a majority of patients suffering from diffuse large B-cell lymphoma (DLBCL) achieve long-term remission and are considered cured, while the remaining patients succumb to their disease. In other lymphoma subtypes, such as the heterogenous group of T-cell lymphomas, patients have a more dismal prognosis when treated with chemotherapy, highlighting the unmet medical need to identify novel treatments. The clini...